Safety and Feasibility Assessment of Extending the Flushing Interval in Totally Implantable Venous Access Port Flushing During the Non-treatment Stage for Patients with Breast Cancer

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Dec 19

PMID 36531077

Authors

Yinhuan Wang

Hao Tian

Xianchun Chen

Jiasi Zhang

Li Wang

Haiyan Fan

Yi Zhang

Xiaowei Qi

Shaoyi Hu

Ying Yang

Affiliations

Soon will be listed here.

Abstract

Aim: To investigate the safety and feasibility of extending the flushing interval for the totally implantable venous access port (TIVAP) during the non-treatment stage in patients with breast cancer (BC) by retrospectively analyzing the patients' clinical data, including the incidence of TIVAP-related complications.

Methods: This single-center retrospective study included patients with BC who underwent TIVAP implantation at our hospital between January 2018 and March 2021 during their non-treatment phase and visited the hospital regularly for TIVAP flushing. Among the 1013 patients with BC who received TIVAP implantation, 617 patients were finally included on the basis of the inclusion and exclusion criteria and divided into three groups according to the length of the flushing interval: group 1 (≤30 days, n = 79), group 2 (31-90 days, n = 66), and group 3 (91-120 days, n = 472). The basic characteristics of patients in each group and the incidence of TIVAP-related complications (catheter obstruction, infection, and thrombosis) were analyzed.

Results: No significant intergroup differences were observed in age, body mass index (BMI), tumor stage, pathological staging, implantation approach, chemotherapy regimen, duration of treatment, and TIVAP-related blood return rate (P > 0.05). Among patients from all three groups, 11 cases of catheter pump-back without blood and eight cases of TIVAP-related complications such as infection, thrombosis, and catheter obstruction were recorded. However, no significant differences in TIVAP-related complications were observed among the three groups (P > 0.05).

Conclusion: Extending the TIVAP flushing interval beyond three months during the non-treatment stage in BC patients is safe and feasible and did not increase the incidence of TIVAP-related complications.

Citing Articles

Is it feasible to prolong the flushing interval for totally implantable venous access devices (TIVADs)? A systematic review and meta-analysis.

Liu L, Liang J, Liu Z, Jin Y, Ma C, Zhao X Int J Clin Oncol. 2024; 30(1):40-50.

PMID: 39601969 DOI: 10.1007/s10147-024-02665-2.

References

Wu X, Zhang T, Chen L, Chen X . Prolonging the flush-lock interval of totally implantable venous access ports in patients with cancer: A systematic review and meta-analysis. J Vasc Access. 2020; 22(5):814-821. DOI: 10.1177/1129729820950998. View

Zhang Y, Zhao R, Jiang N, Shi Y, Wang Q, Sheng Y . A retrospective observational study on maintenance and complications of totally implantable venous access ports in 563 patients: Prolonged versus short flushing intervals. Int J Nurs Sci. 2021; 8(3):252-256. PMC: 8283705. DOI: 10.1016/j.ijnss.2021.05.005. View

Lopez-Briz E, Ruiz Garcia V, Cabello J, Bort-Marti S, Carbonell Sanchis R, Burls A . Heparin versus 0.9% sodium chloride locking for prevention of occlusion in central venous catheters in adults. Cochrane Database Syst Rev. 2018; 7:CD008462. PMC: 6513298. DOI: 10.1002/14651858.CD008462.pub3. View

Gorski L, Hadaway L, Hagle M, Broadhurst D, Clare S, Kleidon T . Infusion Therapy Standards of Practice, 8th Edition. J Infus Nurs. 2021; 44(1S Suppl 1):S1-S224. DOI: 10.1097/NAN.0000000000000396. View

Fornaro C, Piubeni M, Tovazzi V, Cosentini D, Gelmi M, Rota G . Eight-week interval in flushing and locking port-a-cath in cancer patients: A single-institution experience and systematic review. Eur J Cancer Care (Engl). 2018; 28(2):e12978. DOI: 10.1111/ecc.12978. View

Heibl C, Trommet V, Burgstaller S, Mayrbaeurl B, Baldinger C, Koplmuller R . Complications associated with the use of Port-a-Caths in patients with malignant or haematological disease: a single-centre prospective analysis. Eur J Cancer Care (Engl). 2009; 19(5):676-81. DOI: 10.1111/j.1365-2354.2009.01115.x. View

Tabatabaie O, Kasumova G, Eskander M, Critchlow J, Tawa N, Tseng J . Totally Implantable Venous Access Devices: A Review of Complications and Management Strategies. Am J Clin Oncol. 2017; 40(1):94-105. DOI: 10.1097/COC.0000000000000361. View

Perez Fidalgo J, Garcia Fabregat L, Cervantes A, Margulies A, Vidall C, Roila F . Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol. 2012; 23 Suppl 7:vii167-73. DOI: 10.1093/annonc/mds294. View

Zhou J, Qian S, He W, Han G, Li H, Luo R . Implanting totally implantable venous access port via the internal jugular vein guided by ultrasonography is feasible and safe in patients with breast cancer. World J Surg Oncol. 2014; 12:378. PMC: 4265500. DOI: 10.1186/1477-7819-12-378. View

10.

Sallah S, Wan J, Nguyen N . Venous thrombosis in patients with solid tumors: determination of frequency and characteristics. Thromb Haemost. 2002; 87(4):575-9. View

11.

Beckers M, Ruven H, Seldenrijk C, Prins M, Biesma D . Risk of thrombosis and infections of central venous catheters and totally implanted access ports in patients treated for cancer. Thromb Res. 2009; 125(4):318-21. DOI: 10.1016/j.thromres.2009.06.008. View

12.

Johansson E, Engervall P, Bjorvell H, Hast R, Bjorkholm M . Patients' perceptions of having a central venous catheter or a totally implantable subcutaneous port system-results from a randomised study in acute leukaemia. Support Care Cancer. 2008; 17(2):137-43. DOI: 10.1007/s00520-008-0449-6. View

13.

Lyman G, Carrier M, Ay C, Di Nisio M, Hicks L, Khorana A . American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021; 5(4):927-974. PMC: 7903232. DOI: 10.1182/bloodadvances.2020003442. View

14.

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

15.

Schulmeister L . Preventing and managing vesicant chemotherapy extravasations. J Support Oncol. 2010; 8(5):212-5. DOI: 10.1016/j.suponc.2010.09.002. View

16.

Tan L, Sun Y, Zhu L, Lei X, Liang D, Rao N . Risk factors of catheter-related thrombosis in early-stage breast cancer patients: a single-center retrospective study. Cancer Manag Res. 2019; 11:8379-8389. PMC: 6750851. DOI: 10.2147/CMAR.S212375. View

17.

Diaz J, Rai S, Wu X, Chao J, Dias A, Kloecker G . Phase II Trial on Extending the Maintenance Flushing Interval of Implanted Ports. J Oncol Pract. 2017; 13(1):e22-e28. DOI: 10.1200/JOP.2016.010843. View

18.

Solinas G, Platini F, Trivellato M, Rigo C, Alabiso O, Galetto A . Port in oncology practice: 3-monthly locking with normal saline for catheter maintenance, a preliminary report. J Vasc Access. 2017; 18(4):325-327. DOI: 10.5301/jva.5000740. View

19.

Gradishar W, Moran M, Abraham J, Aft R, Agnese D, Allison K . Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(6):691-722. DOI: 10.6004/jnccn.2022.0030. View

20.

Rasero L, Golin L, Ditta S, Di Massimo D, Dal Molin A, Piemonte G . Effects of prolonged flushing interval in totally implantable venous access devices (TIVADs). Br J Nurs. 2018; 27(8):S4-S10. DOI: 10.12968/bjon.2018.27.8.S4. View